Alphabet’s AI-powered drug discovery company, Isomorphic Labs, is preparing to take its first major leap into the real world. After years of development, the company says it’s now gearing up for human ...

Isomorphic Labs, backed by Google's parent company Alphabet, is preparing for its first human clinical trials for cancer drugs designed entirely by artificial intelligence.

Isomorphic Labs is a London-based drug developer that’s owned and operated by Alphabet Inc. The company was founded in 2021 ...

Isomorphic Labs, a DeepMind spinoff, is close to starting human trials for AI-designed drugs. The company aims to speed up drug discovery, reduce costs, and improve success rates in medicine.

The oncology drug created by Isomorphic Labs using Google DeepMind’s AlphaFold 3 tool could be pivotal for cancer treatment.